Pressroom

See all trending topics »Trending Topics

Check out the latest cancer-related news and also see who is readily available to offer reliable information, expert commentary, and reaction to today's headlines.
Contact a media coordinator »

Exciting Developments, New Research in Breast Cancer: San Antonio Breast Cancer Symposium

Memorial Sloan Kettering breast cancer experts are available to comment on breaking news out of this year’s annual meeting set to take place December 9 through 13.

Monday, December 8, 2014
Major Developments in Hematology-Oncology to Be Reported at ASH Annual Meeting

The largest hematology-oncology meeting in the world will take place in San Francisco from December 6 through 9. Memorial Sloan Kettering experts are available to comment on breaking news out of the meeting.

Tuesday, December 2, 2014
Memorial Sloan Kettering Team Makes Key Discovery in Understanding Immunotherapy’s Successes—And Its Failures

A collaborative team of leaders in the field of cancer immunology has made a key discovery that advances the understanding of why some patients respond to ipilimumab, an immunotherapy drug, while others do not.

Wednesday, November 19, 2014

See all press releases »Press Releases

Pictured: Eytan Stein
Memorial Sloan Kettering Study Shows New Kind of Targeted Drug Has Promise for Leukemia Patients

A new type of cancer therapy that targets an oncometabolite produced dramatic results in patients with advanced leukemia in an early-phase clinical trial.

Sunday, December 7, 2014
Studies Led by Memorial Sloan Kettering Investigators Show Immunotherapy Drugs Improve Outcomes in Hodgkin Lymphoma Patients

A number of scientific breakthroughs have led to the development of drugs that unleash the power of the immune system to recognize and attack cancer. For Classical Hodgkin lymphoma patients, two phase I studies are already demonstrating dramatic results.

Saturday, December 6, 2014
Pictured: Craig Moskowitz
Positive Data from Pivotal Phase III Study Could Improve Standard of Care for Hodgkin Lymphoma Patients

In a late-stage clinical trial, Hodgkin lymphoma patients who received brentuximab vedotin post-transplant lived longer without disease progression than patients who received only supportive care.

Saturday, December 6, 2014

See all story starters »Story Starters

Need story ideas? Use our evergreen story suggestions to generate new content or complement something you're already working on.

See all blog posts »On Our Blog

Pictured: Peter Kingham
Perspective
Team Spirit: A Glimpse Inside a Disease Management Meeting

Memorial Sloan Kettering’s top cancer specialists come together to consult on complex cases at weekly Disease Management Team meetings.

Monday, December 15, 2014
Pictured: Eytan Stein
In the Clinic
Can Cells Be Turned from Cancerous to Normal?

An experimental drug for blood cancers with certain genetic mutations is showing promise in early-stage trials.

Thursday, December 11, 2014
Pictured: Louis Voigt
Q&A
Each Patient Is a Unique Human Being, Not a Disease or a Group of Symptoms

MSK critical care physician Louis Voigt is a firm believer in a holistic approach to the practice of medicine, as well as to his patients and their loved ones.

Monday, December 8, 2014

MSK News Highlights

Watch highlights including news coverage of recent scientific and clinical developments at Memorial Sloan Kettering, our physicians and scientists in the national spotlight, and our amazing staff and programs.

Watch Video »

See all media coverage »Media Coverage

Cancer: Unpronounceable Drugs, Incomprehensible Prices

Epidemiologist Peter Bach commented on the continued rise in cancer drug prices.

Wednesday, August 13, 2014
Gene Mutation Discovered In Breast Cancer Research

Clinical geneticist Kenneth Offit discussed new findings about a gene called PALB2 that is linked to breast cancer.

Friday, August 8, 2014
Early Stem Cell Transplant Vital in 'Bubble Boy' Disease

Pediatric oncologist Richard O’Reilly discussed a study he led that confirms that transplantation for severe combined immunodeficiency works well in very young children.

Thursday, July 31, 2014

For Journalists

Contact Media Staff

Jeanne D'Agostino
Media Relations Manager
Emily O'Donnell
Senior Communications Associate, Department of Surgery
Courtney Nowak
Senior Media Relations Associate
Caitlin Hool
Senior Media Associate
Rebecca Williams
Media Associate

For press inquiries, our Media Staff are available by calling 646-227-3573 or by dialing the numbers above. Our office hours are Monday - Friday, 9:00 AM to 5:00 PM.

After hours, please contact the hospital's page operator at 212-639-7900 and ask for the Public Affairs representative on-call.

#1 in Cancer Care

MSK Named #1 by U.S. News

News & World Report named Memorial Sloan Kettering the top hospital for cancer care in the nation. We're honored, and patient care will always be our top priority.

Live and Remote Broadcast Capabilities

Our experts can offer live broadcast interviews using the on-site studio system. To book an expert interview using our on-site broadcast studio contact our Media Staff.

Subscribe to Our
E-Newsletter

Our e-mail newsletter for journalists offers the latest advances in cancer research and treatment, including story ideas, institutional milestones and plans, and newsworthy staff accomplishments.

Sign Up

Read recent issues »